The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy.
Minimal residual disease (MRD) levels were determined by multi-parameter flow cytometry in 45 younger adult patients ( pound60 years old) with acute myeloid leukemia (AML) in complete remission. Data were collected after induction (MRD1; n=43) and/or at the end of post-remission chemotherapy or before stem cell transplantation (SCT)(MRD2; n=31). Patients with detectable MRD2 who underwent allogeneic or autologous SCT had significantly better 5-year relapse-free survival than patients not transplanted (80%, 53% and 0%, respectively p=0.003). Therefore allogeneic SCT should be considered in younger adult AML patients with detectable MRD at the end of post-remission chemotherapy. Autologous SCT may be an alternative for patients not eligible for allogeneic SCT.
Laane
Edward
E
Department of Pathology and Cytology, Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden.
Derolf
Asa Rangert
AR
Björklund
Elisabet
E
Mazur
Joanna
J
Everaus
Hele
H
Söderhäll
Stefan
S
Björkholm
Magnus
M
Porwit-MacDonald
Anna
A
D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001752:Blast Crisis / Q000473:pathology; D001854:Bone Marrow Cells / Q000473:pathology; D005434:Flow Cytometry; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D018365:Neoplasm, Residual / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents